Attached files

file filename
10-K - ANNUAL REPORT - REGENERON PHARMACEUTICALS, INC.regeneron_10k.htm
EX-31.2 - CERTIFICATION OF CFO PURSUANT TO RULE 13A-14(A) - REGENERON PHARMACEUTICALS, INC.exhibit31-2.htm
EX-31.1 - CERTIFICATION OF CEO PURSUANT TO RULE 13A-14(A) - REGENERON PHARMACEUTICALS, INC.exhibit31-1.htm
EX-23.1 - CONSENT OF PRICEWATERHOUSECOOPERS LLP - REGENERON PHARMACEUTICALS, INC.exhibit23-1.htm
EX-10.1.8 - FORM OF OPTION AGREEMENT AND RELATED NOTICE OF GRANT - REGENERON PHARMACEUTICALS, INC.exhibit10_1-8.htm
EX-10.1.7 - FORM OF RESTRICTED STOCK AWARD AGREEMENT AND RELATED NOTICE OF GRANT - REGENERON PHARMACEUTICALS, INC.exhibit10_1-7.htm
EX-10.11.7 - SEVENTH AMENDMENT TO LEASE - REGENERON PHARMACEUTICALS, INC.exhibit10_11-7.htm
EXCEL - IDEA: XBRL DOCUMENT - REGENERON PHARMACEUTICALS, INC.Financial_Report.xls

Exhibit 32
 
Certification of CEO and CFO Pursuant to
18 U.S.C. Section 1350,
As Adopted Pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002
 
In connection with the Annual Report of Regeneron Pharmaceuticals, Inc. (the "Company") on Form 10-K for the year ended December 31, 2010 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), Leonard S. Schleifer, M.D., Ph.D., as Chief Executive Officer of the Company, and Murray A. Goldberg, as Chief Financial Officer of the Company, each hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge, that:
 
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
 
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
 
  
 
/s/ LEONARD S. SCHLEIFER  
Leonard S. Schleifer, M.D., Ph.D.  
Chief Executive Officer  
February 17, 2011  
   
   
/s/ MURRAY A. GOLDBERG  
Murray A. Goldberg  
Chief Financial Officer  
February 17, 2011